BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-157@catalystbrief.girapphe.com
DTSTAMP:20261118T181601Z
LAST-MODIFIED:20261118T181601Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sanofi Pasteur\, a Sanofi Company — PCV21 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of the Safety and Immunogenic
 ity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccin
 e (PCV21) in Healthy Infants\, Toddlers\, Children\, and Adolescents.\nSou
 rce: https://clinicaltrials.gov/study/NCT06838000\nhttps://catalystbrief.g
 irapphe.com/e/157?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/157?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
